Post-Conference Workshop Day

Even with 2026 seeing ADCs continue to rival oncology standard of care performance, translation of ADC toxicity profiles to the clinic remains the largest hurdle to widen ADC therapeutic index and accomplish widespread impact for patients in need. 

Led by long-standing ADC toxicity experts, join your peers to understand ADC class effect toxicities and best leverage preclinical tools and historical learnings to effectively characterize safety profiles and predict ADC tolerability in the clinic. 

Workshop highlights include:

• Discussing ADC class effect toxicities observed in the clinic across ocular toxicity, ILD, neutropenia and beyond 
• Delving into deployment and utilization of in vivo and in vitro models to improve prediction of clinical toxicity profiles
• Breaking down lessons learned from successful and failed historical ADC translation to inform design, engineering and characterization of better ADCs with wider therapeutic index 

As an increasingly diverse array of ADCs containing different payloads and linkers are developed to tackle different tumor targets, understanding how bioconjugate design contributes and accumulates to performance in the clinic is vital to set up your therapy for success.

Take part in this workshop exploring recent case-study examples to contextualize and understand the performance of different ADC designs to understand what really makes a clinically effective ADC.

Workshop highlights include:

• Accurately correlating and characterizing antibody, linker, payload, and overall conjugate contributions to ADC clinical performance
• Delving into ADC clinical case studies to evaluate differentiated design impact on safety and efficacy profiles to understand what makes a clinically effective ADC
• Finding the right match: Optimizing ADC design to improve payload target pairing

Properly understanding ADC PK/PD and in vivo stability is crucial to best inform clinical performance and trial design.

Don’t miss this session exploring bioanalytical strategy across development phases, insights into LCMS method development, and in vivo biotransformation impacting PK/PD and stability properties to understand how to efficiently leverage bioanalytical technologies to best characterize your ADC clinical material.

Workshop highlights include:

• Explaining the significance of ADC bioanalysis across reagent characterization and immunogenicity in early-stage ADC development
• Contextualizing bioanalytical analysis to understand clinical PK/PD consequences and impact on clinical development strategy
• Laying out regulatory expectations and emerging technologies for comprehensive ADC bioanalytical workflows across development phases

Selecting and maintaining strong relationships with CDMO and regulator stakeholders is vital to navigate ADC manufacturing and supply chain in a timely, cost-effective and regulatory compliant manner to bring more accessible ADC therapies to patients in need.

Join this strategy-led workshop session to troubleshoot and optimize CMC stakeholder relationships to ensure ADC GMP quality and best set up regulatory submissions for success.

Workshop highlights include:

• Debating and navigating differences in opinion between industry and outsourcing partners at different stages of ADC manufacturing
• Understanding best strategies to optimize manufacturing stakeholder relationships and ensure ADC quality under GMP requirements
• Assessing best approaches for ADC regulatory submissions with discussion of science-based justifications to support alternative ADC control strategies